# A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

> **NCT04004611** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 26 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Mirikizumab

## Key facts

- **NCT ID:** NCT04004611
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-18
- **Primary completion:** 2023-03-15
- **Final completion:** 2023-03-15
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04004611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04004611, "A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04004611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*